Neutralising antibodies to interferon-β - Measurement, clinical relevance, and management

Journal of Neurology

Volumn 253, Issue SUPPL. 6, 2006, Pages

  Sørensen, Per Soelberg ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Beta interferon; Multiple sclerosis; Neutralising antibody

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; HUMAN; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 33750722090     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-6004-9     Document Type: Conference Paper

References (19)

1. Clanet M, Radue EW, Kappos L et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
2. Durelli L, Verdun E, Barbero P et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
3. European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
4. Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
5. Kappos L, Clanet M, Sandberg-Wolheim M et al. (2005) Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40-47
6. Panitch H, Goodin DS, Francis G et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
7. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS; Danish Multiple Sclerosis Group (2006) Persistence of neutralizing antibodies after discontinuation of IFN-beta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 12(3):247-252
8. Polman C, Kappos L, White R et al. (2003) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37-43
9. PRISMS Study Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636
10. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52:1277-1279
11. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL et al. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48:706-712
12. Rudick RA, Simonian NA, Alam JA et al. (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50:1266-1272
13. Sørensen PS, Ross C, Clemmesen KM et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
14. Sørensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K (2005) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33-39
15. Sørensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C; EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817-827
16. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504
17. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
18. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47:889-894
19. The North American Study Group on interferon beta-1b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63:1788-1795